Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926550 | 0.89 | NPC1 (0.52) | NPC1RAB9APLAUMCHR1HTR2C | |
| SCHEMBL2929336 | 0.89 | MCHR1 (0.55) | NPC1RAB9APLAUMCHR1HTR2C | |
| SCHEMBL2928015 | 0.88 | MCHR1 (0.63) | NPC1RAB9AMCHR1HTR2CMAPT | |
| SCHEMBL2922469 | 0.88 | MCHR1 (0.56) | NPC1RAB9AMCHR1HTR2CMAPT | |
| SCHEMBL2952393 | 0.80 | MCHR1 (0.77) | NPC1RAB9APLAUMCHR1HTR2C | |
| SCHEMBL2926775 | 0.79 | MCHR1 (0.54) | NPC1RAB9AMCHR1HTR2CSMN1; SMN2 | |
| SCHEMBL2921681 | 0.79 | MCHR1 (0.76) | NPC1RAB9APLAUMCHR1HTR2C | |
| SCHEMBL2925373 | 0.79 | MCHR1 (0.53) | NPC1RAB9AMCHR1HTR2CMAPT | |
| SCHEMBL2921048 | 0.79 | KDM4E (0.51) | NPC1RAB9AMCHR1MAPTALDH1A1 | |
| SCHEMBL2924745 | 0.77 | MCHR1 (0.58) | NPC1RAB9APLAUMCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | NPC1 1013/4885RAB9A 1132/4885PLAU 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.